SCHEMBL21044296

SCHEMBL21044296

CCOC(=O)C1CCCc2sc(NS(=O)(=O)C3CC3)nc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PARP1 P09874 1/20 0.39
GAA P10253 4/20 0.35
KDM4E B2RXH2 3/20 0.35
HSD17B10 Q99714 3/20 0.35
RECQL P46063 1/20 0.35
PDK1 Q15118 1/20 0.35
CTPS1 P17812 5/20 0.34
MAPT P10636 3/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
LMNA P02545 1/20 0.34
CTPS2 Q9NRF8 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
CYP2C9 P11712 1/20 0.32
TLR4 O00206 1/20 0.32
PSMD14 O00487 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21044359 0.93 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ASMN1; SMN2PARP1
SCHEMBL21044054 0.83 CTPS1 (0.34) ALDH1A1SMN1; SMN2GAAHSD17B10CTPS1
SCHEMBL13314787 0.79 PARP1 (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2PARP1
SCHEMBL3539844 0.79 PARP1 (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2PARP1
SCHEMBL909067 0.79 ALDH1A1 (0.46) ALDH1A1MEN1KMT2ASMN1; SMN2PARP1
Bromide SCHEMBL3536459 0.78 PARP1 (0.43) ALDH1A1MEN1KMT2ASMN1; SMN2PARP1
SCHEMBL4877966 0.78 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ASMN1; SMN2PARP1
SCHEMBL3929167 0.78 ALDH1A1 (0.45) ALDH1A1MEN1KMT2ASMN1; SMN2PARP1
SCHEMBL4807243 0.77 PARP1 (0.47) ALDH1A1MEN1KMT2ASMN1; SMN2PARP1
SCHEMBL999312 0.77 PARP1 (0.42) ALDH1A1MEN1KMT2ASMN1; SMN2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717459-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 EP disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-20210002269-A1 COMPOUNDS STEP PHARMA S.A.S. (FR) 2021-01-07 US disclosed
EP-3492454-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2019-06-05 EP disclosed
EP-3492454-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2019-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 ALDH1A1 3425/4885MEN1 4301/4885KMT2A 4442/4885
US-20210002269-A1 COMPOUNDS UGT1A1, CYP1A1, CYP19A1 ALDH1A1 181/4885MEN1 192/4885KMT2A 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.